Biotech / Finance

Esperion Therapeutics Says FDA Has Lowered The Bar For Its Heart Drug

From The Medicine Show
March 20, 2017 - 7:32am
Esperion Therapeutics says the Food and Drug Administration has agreed that the company's medicine, bempadoic acid, could be approved based on blood test results, before a larger study proving it prevents heart attacks, strokes, heart procedures or deaths has been completed.

Continue reading this article »